A 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Trial Profile

A 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2017 New trial record
    • 07 Sep 2017 According to an Intra-Cellular Therapies media release, further data from this study will be presented at upcoming medical conferences.
    • 07 Sep 2017 Topline results from the open label part of the study (n=302), published in an Intra-Cellular Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top